VDAC1 and myocardial infarction: Thus, further investigation is warranted to determine whether MAMs and IP3R2-GRP75-VDAC1 complex in myocardial cells could serve as novel clinical targets for pharmacological intervention in myocardial infarction, by modulating intracellular calcium homeostasis after AMI.